CHENNAI : Pfizer has announced the launch of a new therapy, a BCMA (B-Cell Maturation Antigen) directed bi-specific antibody in India for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). The new medication, for those who have received 4 prior therapies, delivers a clinically meaningful improvement in progression-free survival (PFS) and a durable response for RRMM Patients, while maintaining an established safety profile.
Elranatamab is now available in India as a ready-to-use, convenient fixed-dose subcutaneous injection. It offers the option of weekly administration, followed by every-other-week dosing for patients who respond after 24 weeks of weekly treatment. Subcutaneous administration results in less time spent at the clinic for the patient and the caregiver, to have the treatment administered.
This therapy sets a new standard in comprehensive multiple myeloma care by providing a new option for heavily pre-treated patients. Elranatamab provides a therapy that effectively activates the body’s immune system to attack cancer cells. It destroys cancer cells by binding to both CD3, a protein found on the surface of T cells (a type of white blood cell), and BCMA, a protein found on the surface of B cells (a second type of white blood cell).
Meenakshi Nevatia, Country President, Pfizer India, said, “Patients with relapsed or refractory multiple myeloma often face a long and challenging journey, with significant physical and emotional burden. The introduction of Elranatamab in India marks another step forward in bringing a highly innovative, ready-to-use targeted therapy that combines strong clinical efficacy with the convenience of every other week dosing for patients who are responding well to weekly therapy. In addition to extending survival, our aim is to help patients live better. At Pfizer, our focus remains on addressing such critical unmet needs through meaningful scientific breakthroughs and advancing both care and outcomes.”
Multiple myeloma, that ranks as the second most common type of blood cancer globally, also poses a significant challenge in India , being an aggressive and currently incurable blood cancer. Despite treatment advances, numerous patients eventually relapse, often requiring multiple lines of therapy and facing an increased symptom burden. Pfizer’s new therapy seeks to bridge this gap by offering advanced, off-the-shelf treatment options, addressing the longstanding medical need for innovative solutions to better manage multiple myeloma and prolong survival.
